Final results from the DUNE trial (GETNE 1601): Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins

#3391

Introduction: Activity of immune checkpoint blockade in advanced NENs remains controversial.

Aim(s): To evaluate the efficacy and safety of dual targeting inhibition of PD-L1 and CTLA-4 in all spectrum of advanced NENs.

Materials and methods: Eligible patients (pts) were enrolled in 4 cohorts: Typical/atypical lung carcinoids (C1), G1/2 gastrointestinal (C2), G1/2 pancreatic (C3) and G3 gastroenteropancreatic (C4) NENs; all pts had progressed to standard therapies. Central pathology review was done in C4. Pts received durvalumab (D) 1500 mg up to 13 cycles and tremelimumab (T) 75 mg up to 4 cycles, every 4 weeks. Primary objective was 9-month (m) clinical benefit rate (CBR) for C1-3 and 9-m overall survival rate (OS) for C4. Correlation of PD-L1 expression and efficacy was evaluated.

Conference:

Presenting Author:

Authors: Capdevila J, Teulé A, Hernando J, López C, Garcia-Carbonero R,

Keywords: advanced neuroendocrine neoplasm, Immunotherapy, durvalumab, tremelimumab,